RecruitingC3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Eligible age
12–100 yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
Sponsor: Novartis Pharmaceuticals
You may qualify if…
- ✓ \- Patients must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
You may not qualify if…
- ✕ Severe concurrent co-morbidities, e.g. advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), or any illness or medical condition that in the opinion of the investigator and sponsor is likely to prevent the patient from safely tolerating LNP023 or complying with the requirements of the study
- ✕ Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to screening, or the presence of fever ≥ 38oC (100.4oF) within 7 days prior to screening.
- ✕ History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects
- ✕ History of HIV or any other immunodeficiency disease
- ✕ Other protocol-defined inclusion/exclusion criteria may apply
Where it's recruiting
Source: ClinicalTrials.gov · NCT03955445 · last updated 2026-08-07